KRON - Cancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer Study | Benzinga
Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the company has decided not to proceed to phase 2.
This decision was based on a review of the data from 24 patients across the four dose cohorts (20 – 90 mg lanraplenib in combination with 120 mg gilteritinib).
While there were blast reductions in some patients, no complete response (CR) or CR with partial hematologic recovery (CRh) was observed, with several patients discontinuing early in treatment.
The company is open to further development of lanraplenib, a SYK inhibitor, with a partner.
Kronos Bio also announced the designation of a new development candidate, KB-9558, which targets the lysine acetyltransferase domain ...